Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancer
Open Access
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (R01 CA76184)
- University of Washington (CHD1-KO)
- University of Washington (SCR_018361)
- University of Washington (CHD1-WT)
- U.S. Department of War (PC150211)
- U.S. Department of War (P50 CA269011)
- University of Wisconsin Carbone Cancer Center (SCR_017757)
- University of Wisconsin Carbone Cancer Center (SCR_025085)
- University of Wisconsin Carbone Cancer Center (P30 CA014520)
- Fondation pour la Médecine de Laboratoire
- National Institutes of Health
This publication has 45 references indexed in Scilit:
- Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancerCancer Letters, 2024
- Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin DysregulationCancer Cell, 2020
- CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate TumorigenesisCancer Cell, 2019
- Molecular Subtypes of Prostate CancerCurrent Oncology Reports, 2018
- LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer TherapeuticsThe Prostate, 2017
- The Molecular Taxonomy of Primary Prostate CancerCell, 2015
- EZH2, an epigenetic driver of prostate cancerProtein & Cell, 2013
- Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in CancerMolecular Cell, 2013
- A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarraysHuman Pathology, 2013
- Distinct Factors Control Histone Variant H3.3 Localization at Specific Genomic RegionsCell, 2010